CHARLOTTESVILLE, Va., April 16, 2012 /PRNewswire/ -- HemoShear, LLC, a biotechnology research company and leading developer of human and animal cell-based surrogate systems for discovery and assessment of new drug compounds, has been invited to present at the American Heart Association's Arteriosclerosis, Thrombosis and Vascular Biology (ATVB) conference. The conference will be held April 18-20, 2012 at the Hilton Chicago, 720 South Michigan Avenue in Chicago, Illinois.
The company will occupy booth No. six for recruiting purposes and present two scientific abstracts:
Atheroprone Hemodynamics and Oxidized Phospholipids Enhance Endothelial and Smooth Muscle Inflammatory Signaling
The Thrombotic Potential of the Endothelium Is Regulated by Hemodynamic Flow
HemoShear team members attending the conference include Brett Blackman, Ph. D., co-founder, Chief Scientific Officer; Brian Wamhoff, Ph.D., co-founder, Vice President of Research and Development; Nicole Hastings, Ph.D., Vice President of Operations; Ryan Feaver, Ph.D., Scientific Director; Michael Simmers, Ph.D., Scientific Director.
About HemoShear, LLC
HemoShear creates human-relevant systems that accurately replicate the biology of organ systems and diseases throughout drug discovery and development. Working in strategic partnerships with pharmaceutical, biotechnology and medical device companies, HemoShear generates meaningful data to increase confidence in decision-making, reduce risk of costly failures and identify efficacious therapies. HemoShear's science leads to new medicines and improves human health.
|SOURCE HemoShear, LLC|
Copyright©2010 PR Newswire.
All rights reserved